NEW ORLEANS — In the CLEAR Outcomes trial, bempedoic acid reduced risk for major CV events by 13% compared with placebo, including a 23% lower risk for MI, among adults with a history of CVD or at high risk deemed statin intolerant.Bempedoic acid (Nexletol, Esperion Therapeutics) was FDA approved in 2020 for lowering LDL, but the effects of the drug on CV outcomes have not been assessed,
Healio and Cardiology Today have compiled a list of the top headlines in cardiology from February 2023. Reader were most interested in CVD prevention recommendations provided by ChatGPT; the effect of “food swamp” communities on stroke risk; recent updates in women’s heart health and cardio-obstetrics; and more.
WASHINGTON — In the ADAPT-TAVR trial of patients who had transcatheter aortic valve replacement and no indication for long-term anticoagulation, edoxaban did not improve leaflet thrombosis compared with dual antiplatelet therapy.There was also no difference between the edoxaban (Savaysa, Daiichi Sankyo) and DAPT groups in cerebral thromboembolism and neurological or neurocognitive function,
North American COVID-19 Myocardial Infarction Registry (NACMI) data simultaneously presented at ACC.22 and published in Journal of the American College of Cardiology. Two-year data analysis show significant changes in management and outcomes with STEMI and COVID-19 over course of pandemic.
WASHINGTON — In well-treated patients with chronic HF with reduced ejection fraction, omecamtiv mecarbil did not improve measures of exercise capacity over 20 weeks compared with placebo, researchers reported. Exercise is a “cardinal manifestation” of HF but is not improved by current medical therapies, G. Michael Felker, MD, MHS, professor of medicine at Duke Clinical Research